This review explores the interplay between genetic susceptibility and myocardial inflammation in cardiomyopathies, highlighting emerging therapeutic approaches targeting inflammatory pathways.
ABSTRACT Genetic variants that impair cardiac function or predispose individuals to autoimmune diseases can influence both the risk and severity of inflammatory heart diseases, including lymphocytic myocarditis and cardiac sarcoidosis. We review recent clinical and experimental studies that describe the emerging interplay between genetic susceptibility and active myocardial inflammation. We summarize the current perspective on the mechanisms of inflammatory pathways and gene‐immune interactions, and explore the emerging therapeutic approaches aimed at targeting inflammation in genetic cardiomyopathies.
Peretto et al. (Sun,) conducted a review in Cardiomyopathies and inflammatory heart diseases. This review explores the interplay between genetic susceptibility and myocardial inflammation in cardiomyopathies, highlighting emerging therapeutic approaches targeting inflammatory pathways.